Mango Medical
Winter 2026 NewFoundation models for planning orthopedic surgery
Mango Medical builds agentic surgical planning AI for orthopedic surgery. We deliver surgeon-ready plans in minutes instead of days. 8-figure LOI from a top orthopedic company. Pursuing FDA 510(k) clearance. We're building a future where every surgery follows a personalized plan.
AI Investor Summary
Mango Medical is developing agentic surgical planning AI for orthopedic surgery, leveraging foundation models to deliver surgeon-ready plans in minutes. With a strong founding team from top tech and academia, a significant 8-figure LOI, and a clear regulatory path, they are poised to disrupt a large and growing market. The key challenge will be ensuring surgeon adoption and navigating the complexities of medical device regulation.
Key Highlights
- ● 8-figure LOI from a top orthopedic company
- ● Founders with strong technical backgrounds from top universities (Oxford, Berkeley) and leading tech companies (Google, Microsoft)
- ● Application of foundation models to a high-value, complex medical domain (orthopedic surgery planning)
- ● Pursuing FDA 510(k) clearance, indicating a clear path to market
Risk Factors
- ● Regulatory approval timeline and potential challenges with FDA 510(k)
- ● Surgeon adoption and integration into existing clinical workflows
- ● Competition from other AI surgical planning solutions or established medical device companies
- ● Data acquisition and annotation for training foundation models in a highly specialized field
Founders
Adrian Kilian is a co-founder of Mango Medical, a Y Combinator startup focused on improving healthcare access. His background likely includes experience in technology and healthcare, given the company's mission. He is a graduate of the University of Oxford.
Jorge Padilla Perez is the co-founder of Mango Medical, a Y Combinator startup focused on improving healthcare access. His background includes experience in product management and engineering, with a strong emphasis on building and scaling technology solutions. He is dedicated to leveraging technology to address critical challenges in the healthcare industry.
Score Breakdown
Strong technical team with excellent academic backgrounds (Oxford, Berkeley) and prior experience at top tech companies (Google, Microsoft). Adrian's focus on healthcare access and Jorge's product/engineering expertise at scale are highly relevant. The combination of deep technical talent and business acumen is a significant strength. [Boost +1: Founder from Google]
Large addressable market in orthopedic surgery planning, which is ripe for AI disruption. The trend towards personalized medicine and the potential for AI to improve efficiency and outcomes create strong tailwinds. The timing for AI adoption in surgical planning appears favorable, especially with the increasing complexity of procedures and the need for cost-effectiveness. Regulatory hurdles (FDA) are present but manageable with a clear path.
The use of foundation models for surgical planning is technically differentiated and has the potential for significant improvement over existing methods. The promise of surgeon-ready plans in minutes is compelling. Defensibility will come from proprietary data, model performance, and integration into clinical workflows. UX quality will be critical for surgeon adoption, and platform potential exists if it can expand beyond orthopedic planning.
Early stage with promising signals. An 8-figure LOI from a top orthopedic company is a very strong validation. Acceptance into YC Winter 2026 is a positive signal. Pursuing FDA 510(k) clearance indicates a clear regulatory strategy. However, actual revenue and user adoption metrics are not yet available, hence the score reflects potential rather than realized traction. [Boost +3: Tier-1 VC: accel; Revenue/ARR mentioned]
News
Mango Medical simulates orthopedic surgeries using CT scans, delivering surgeon-ready 3D plans rapidly and has a $10M ARR LOI from a top orthopedic company, while pursuing FDA 510(k) clearance.
Mango Medical uses AI to generate patient-specific 3D reconstructions and preoperative surgical plans in under three minutes, aiming to become the standard for fracture treatment planning.
ImmunoACT has partnered with Mango Sciences to introduce innovative financing options for their CAR-T therapy, NexCAR19™, aiming to improve accessibility for cancer patients in India.
Mango Medical has been accepted into the highly competitive Y Combinator Winter Batch 2026, and is the only company in the batch pursuing FDA approval for a Medtech product.
Mango Medical is developing agentic surgical planning AI for orthopedic surgery, aiming to deliver surgeon-ready plans in minutes and has an 8-figure LOI from a major orthopedic company.
Mango Medical has launched an AI platform that uses CT scans and X-rays to plan orthopedic surgeries, including implant sizes and approaches, in seconds.
Mango Medical, a YC W26 startup, has secured a $10M ARR Letter of Intent from a top orthopedic company and is pursuing FDA 510(k) clearance for its AI-driven surgical planning API.
Quick Info
- Batch
- Winter 2026
- Team Size
- 3
- Location
- Unspecified
- Founders
- 2
- Scraped
- 4/10/2026